Dexcel Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DEXCEL
DEXCEL has seventeen approved drugs.
There are seven US patents protecting DEXCEL drugs. There is one tentative approval on DEXCEL drugs.
Summary for Dexcel
| US Patents: | 7 |
| Tradenames: | 14 |
| Ingredients: | 14 |
| NDAs: | 17 |
| Patent Litigation for Dexcel: | See patent lawsuits for Dexcel |
Drugs and US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dexcel Ltd | ISOSORBIDE MONONITRATE | isosorbide mononitrate | TABLET, EXTENDED RELEASE;ORAL | 075522-002 | Sep 20, 2016 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel Ltd | DICLOFENAC SODIUM | diclofenac sodium | TABLET, EXTENDED RELEASE;ORAL | 076201-001 | Nov 6, 2002 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel | NINTEDANIB ESYLATE | nintedanib esylate | CAPSULE;ORAL | 219819-001 | Apr 2, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Dexcel
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Dexcel Pharma | OMEPRAZOLE | omeprazole | TABLET, DELAYED RELEASE;ORAL | 022032-001 | Dec 4, 2007 | 9,023,391 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,023,082 | ⤷ Start Trial |
| Dexcel Pharma | PERIOCHIP | chlorhexidine gluconate | TABLET;DENTAL | 020774-001 | May 15, 1998 | 5,002,769 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for DEXCEL drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Dexcel Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2552723 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016174664 | ⤷ Start Trial |
| European Patent Office | 3932396 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2017216789 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Dexcel Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1224170 | 15C0024 | France | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB,SES TAUTOMERES ET SES SELS,EN PARTICULIER LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE NINTEDANIB ET PLUS PARTICULIEREMENT L'ESILATE; REGISTRATION NO/DATE: EU/1/14/954 20141125 |
| 0984957 | 2012/048 | Ireland | ⤷ Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 0124495 | SPC/GB01/006 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727 |
| 1224170 | 17/2015 | Austria | ⤷ Start Trial | PRODUCT NAME: NINTEDANIB UND DESSEN PHYSIOLOGISCH VERTRAEGLICHE SALZE, INSBESONDERE NINTEDANIB ESILAT; REGISTRATION NO/DATE: EU/1/14/954 (MITTEILUNG) 20141125 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
